WaveMan
WaveMan · Company
LXRX · Lexicon Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LXRX Lexicon Pharmaceuticals (LXRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001062822
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $0 priced

Lexicon Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for LEXICON PHARMACEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
DEBBANE RAYMOND
Director
BUY
2026-02-27 SECtraded 2026-02-25
2,000
$3.0K
-7.1%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Feb 23, 2026.
  • +39.4% median (+37.8% mean) 90-day return after 11 previous buys.
  • The trade is 0.1% of the 1,906,186 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEBBANE RAYMOND bought about $3.0K of LXRX on Feb 25, 2026; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
DEBBANE RAYMOND
Director
BUY
2026-02-25 SECtraded 2026-02-23
100,000
$147.0K
-3.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Feb 20, 2026.
  • +42.4% median (+37.9% mean) 90-day return after 10 previous buys.
  • The trade is 5.3% of the 1,904,186 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEBBANE RAYMOND bought about $147.0K of LXRX on Feb 23, 2026; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
DEBBANE RAYMOND
Director
BUY
2026-02-23 SECtraded 2026-02-20
100,000
$148.0K
-2.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Feb 19, 2026.
  • +39.4% median (+36.4% mean) 90-day return after 9 previous buys.
  • The trade is 5.5% of the 1,804,186 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEBBANE RAYMOND bought about $148.0K of LXRX on Feb 20, 2026; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
DEBBANE RAYMOND
Director
BUY
2026-02-23 SECtraded 2026-02-19
50,000
$72.0K
-2.0%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Feb 18, 2026.
  • +38.9% median (+35.3% mean) 90-day return after 8 previous buys.
  • The trade is 2.9% of the 1,704,186 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEBBANE RAYMOND bought about $72.0K of LXRX on Feb 19, 2026; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
DEBBANE RAYMOND
Director
BUY
2026-02-18 SEC
133,688
$176.5K
-4.6%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Feb 17, 2026.
  • +38.3% median (+31.5% mean) 90-day return after 7 previous buys.
  • The trade is 8.1% of the 1,654,186 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEBBANE RAYMOND bought about $176.5K of LXRX on Feb 18, 2026; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 24 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
+60.2% year over year
more than 79% of Pharma & Biotech
Margin
-101.1% net margin
below 58% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.8% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30
more than 55% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LXRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.6%12M
-19%+17%+53%+89%2025-102025-122026-022026-042026-062026-082026-10 2026-02-02 · Artal Group S.A. bought $2.0M2026-02-18 · DEBBANE RAYMOND bought $176.5K2026-02-20 · DEBBANE RAYMOND bought $148.0K2026-02-23 · DEBBANE RAYMOND bought $147.0K2026-02-17 · DEBBANE RAYMOND bought $100.7K2026-02-13 · DEBBANE RAYMOND bought $75.9K2026-02-19 · DEBBANE RAYMOND bought $72.0K2026-02-25 · DEBBANE RAYMOND bought $3.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LXRX: institutional holders (13F)

13F holdings, latest reported quarter
Artal Group S.A.
175,156,062 sh
$420.4M
FMR LLC
51,782,045 sh
$124.3M
Siren, L.L.C.
44,303,518 sh
$106.3M
Sessa Capital IM, L.P.
18,960,836 sh
$45.5M
BlackRock, Inc.
17,348,741 sh
$41.6M

Congress trades in LXRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LXRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LXRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$373.9K position · as of 2026-07-31
0.8%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$2.7M position · as of 2026-06-30
0.6%
PROFUND VP PHARMACEUTICALS
$70.2K position · as of 2026-06-30
0.6%
Invesco NASDAQ Future Gen 200 ETF
$114.1K position · as of 2026-05-31
0.6%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$93.1K position · as of 2026-07-31
0.5%
iShares Micro-Cap ETF
$2.0M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
0 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Michael S. Exton,
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.6M
$5.8M
$1.5M
-40%
n/a
2023
$4.1M
$3.1M
$1.6M
-20%
n/a
2022
$4.2M
$1.2M
$1.6M
-52%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 81 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LXRX financials

Revenue growth
+60.2%
XBRL, annual
Net margin
-101.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$41.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-147.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.29x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-1.26x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-40.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-25.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-25.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$655.7M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$49.8M$31.1M$1.2M$139.0K
Operating income-$48.9M-$197.1M-$171.8M-$100.8M
Net income-$50.3M-$200.4M-$177.1M-$101.9M
EPS (diluted)-0.14-0.63-0.80-0.62
Operating cash flow-$67.9M-$178.8M-$161.9M-$88.9M
Cash$34.3M$66.7M$22.5M$46.3M
Long-term debt$49.4M$100.3M$99.5M$48.6M
Buybacksn/a$1.7M$824.0K$864.0K
SEC XBRL, fiscal years, as known on 2026-10-28

LXRX Stock Sonar score 5/7 axes

Find similar shapesCompare

LXRX ranks highest on growth (79th percentile) and profitability (64th), and lowest on financial health (44th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
64
Inputs
  • Return on equity-40.2% · 60 pct, sector of 545
  • Return on assets-25.7% · 64 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-25.6% · 70 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.29x · 39 pct, sector of 352
  • Cash flow to debt-1.26x · 49 pct, sector of 371
Growth
79
Inputs
  • Revenue growth, YoY+60.2% · 79 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
60
Inputs
  • Funds adding, latest quarter81 · 60 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
63
Inputs
  • Short interest, % of float+11.8% · 34 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.6% · 93 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies